Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Medivir Posts 7-day Data for Osteo Candidate | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Medivir Posts 7-day Data for Osteo Candidate

Cathepsin K inhibitor safe, tolerated at effective levels

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Medivir AB has posted results from its Phase I study of cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and other bone related disorders. The seven-day trial data included the following findings:

  • Serum levels of the bone resorption marker CTX-I were suppressed in a dose-dependent manner with up to 55% at 24 hours post last dose on Day 7
  • Urinary excretion of the cartilage degradation marker CTX-II was reduced in a dose-dependent manner with up to 72% post last dose on Day 7
  • Similar effects were seen in post-menopausal women dosed once daily for 28 days at 100 mg
  • MIV-711 was generally safe and well tolerated at all doses and durations tested

The results, the company contends, demonstrate MIV-711’s safety and tolerability at doses where it potently decreased cartilage degradation and bone resorption as suggested by the biomarker data.

MIV-711 is a potent and selective investigational cathepsin K inhibitor for the treatment of skeletal disorders such as osteoarthritis and osteoporosis. Cathepsin K is an enzyme important for bone and cartilage break-down and inhibition of cathepsin K is expected to have a positive effect on these diseases. Preclinical data with MIV-711 have demonstrated significant reductions of biomarkers for bone and cartilage degradation and encouraging protective effects in experimental models of osteoarthritis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics